Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS) (AIMS)

• ClinicalTrials.gov Identifier: NCT00319488
• Recruitment Status: Completed
• First Posted: April 27, 2006
• Last Update Posted: July 29, 2016
• Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
• Information provided by: National Heart, Lung, and Blood Institute (NHLBI)

Study Description

Brief Summary:

This study will determine the effectiveness of initiating a high-dose inhaled corticosteroid (ICS) or a leukotriene receptor antagonist (LTRA) in addition to an inhaled beta2-agonist (albuterol) at the onset of respiratory tract illness (RTI)-associated symptoms in increasing episode-free days among young children with recurrent severe wheezing.

Condition or disease	Intervention/treatment	Phase
Asthma; Lung Diseases	Drug: Inhaled Corticosteroid (Budesonide); Drug: Leukotriene Receptor Antagonist (Montelukast Sodium); Drug: Inhaled Albuterol	Not Applicable

Detailed Description:

Acute Intervention Management Strategies (AIMS) is a randomized, double-blind, double-dummy, placebo-controlled parallel comparison study that will compare the effectiveness of three treatments, when given at the onset of RTI-associated symptoms, in increasing the proportion of symptom-free days over the entire treatment period of the 5- to 9-month study. There will be a 2-week period to qualify and characterize participants, who at that time will have no lower respiratory tract symptoms other than mild cough. A total of 244 participants will be randomized to one of three treatment groups and followed for the remainder of the fall-winter-early spring season. Participants will receive one of the following treatment regimens for 7 days, at the first sign of RTI-associated symptoms: 1) active ICS plus placebo LTRA plus albuterol inhalation treatments four times daily; 2) active LTRA plus placebo ICS plus albuterol inhalation treatment four times daily; or 3) placebo ICS plus placebo LTRA plus albuterol inhalation treatments four times daily.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 238 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: Childhood Asthma Research and Education (CARE) Network Trial - Acute Intervention Management Strategies (AIMS)
• Study Start Date: February 2004
• Actual Primary Completion Date: November 2006
• Actual Study Completion Date: November 2006

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: 1; Active ICS plus placebo LTRA plus albuterol inhalation treatments four times daily	Drug: Inhaled Corticosteroid (Budesonide); Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.; Drug: Inhaled Albuterol; All participants will receive inhaled albuterol treatments four times a day.
Active Comparator: 2; Active LTRA plus placebo ICS plus albuterol inhalation treatment four times daily	Drug: Leukotriene Receptor Antagonist (Montelukast Sodium); Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.; Drug: Inhaled Albuterol; All participants will receive inhaled albuterol treatments four times a day.
Placebo Comparator: 3; Placebo ICS plus placebo LTRA plus albuterol inhalation treatments four times daily	Drug: Inhaled Albuterol; All participants will receive inhaled albuterol treatments four times a day.

Outcome Measures

Primary Outcome Measures :

1. Proportion of episode-free days as determined by diary cards [ Time Frame: Measured over 12-month follow-up period ]

Secondary Outcome Measures :

1. Time to initiation of first course of oral corticosteroids [ Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization ]
2. Total number of courses of oral corticosteroids [ Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization ]
3. Duration and severity of lower respiratory tract symptoms [ Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization ]
4. Number of wheezing episodes [ Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization ]
5. Time to treatment failure [ Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization ]
6. Measures of patient and family morbidity [ Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization ]
7. Number of unscheduled visits for acute wheezing episodes [ Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization ]
8. Linear growth [ Time Frame: Measured at Weeks 2, 4, 10, 12, 18, 20, 26, 28, 34, 36, 42, 44, 50, and 52 after randomization ]

Eligibility Criteria

• Ages Eligible for Study: 12 Months to 59 Months (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Recurrent episodes (at least two) of wheezing in the context of a RTI, at least one of which must be documented by a health care provider (parental report) over the 12 months prior to study entry, and of which one episode must have occurred within 6 months prior to study entry

• Either two episodes of '1,' OR two episodes of '2,' OR one episode of '1' AND one episode of '2,' defined by the following:

  1. Urgent care visit for acute wheezing (emergency department, urgent care center, or unscheduled primary care physician office visit), which required treatment with a bronchodilator, within 12 months prior to study entry
  2. Episode of wheezing within 12 months prior to study entry, which required treatment with oral corticosteroids not associated with a visit to a health care provider, urgent care center, emergency department, or hospital
• Immunizations are up to date, including varicella (unless the patient has already had clinical varicella)
• Willingness to provide informed consent by patient's parent or guardian

Exclusion Criteria:

• Use of more than six courses of systemic corticosteroids during the 12 months prior to study entry
• More than two hospitalizations for wheezing illnesses within 12 months prior to study entry
• Use of long-term controller medications for asthma (including inhaled corticosteroids, leukotriene modifiers, cromolyn/nedocromil, or theophylline) for 4 or more months (cumulative use) within 1 year prior to study entry
• Any use of long-term controller medications for asthma (including corticosteroids [inhaled or oral], leukotriene modifiers, cromolyn/nedocromil, or theophylline) within the 2 weeks prior to the enrollment visit
• Current treatment with antibiotics for diagnosed sinus disease
• Contraindication of use of systemic corticosteroids
• Prematurity (defined as birth before 36 weeks gestational age)
• Presence of lung disease other than asthma (e.g., cystic fibrosis and BPD)
• Presence of other significant medical illnesses (e.g., cardiac, liver, gastrointestinal, or endocrine disease) that would place the patient at increased risk
• Gastroesophageal reflux under medical therapy
• Immunodeficiency disorders
• History of respiratory failure requiring mechanical ventilation
• History of hypoxic seizure
• Inability to cooperate with nebulization therapy
• Inability to ingest the study drugs
• History of significant adverse reaction to any study medication ingredient
• Current participation, or participation in the month prior to study entry, in another investigational drug study
• Evidence that the family may be unreliable, nonadherent, or likely to move from the clinical center area before study completion
• Persistent symptomatic asthma, as defined as experiencing symptoms (i.e., nocturnal cough, daytime cough, wheezing, difficulty breathing, or symptoms interfering with activities) and/or requiring albuterol use on average 4 or more days per week in the 2-week observation period prior to the randomization visit
• The following scores, based on a 5-point scale with 5 representing very severe symptoms (measured at randomization visit): score equal to or greater than one for albuterol use, wheezing, difficulty breathing, nighttime cough, and asthma symptoms interfering with activities; score greater than 2 for daytime cough on an average of 4 or more days/week during the 2-week observation period
• Failure to complete diary cards at expected levels (at least 80% of days) during the observation period
• Use of long-term controller medications for asthma (e.g., corticosteroids [inhaled or oral], leukotriene modifiers, cromolyn/nedocromil, or theophylline) during the 2-week observation period

Contacts and Locations

Locations

United States, Arizona

University of Arizona, College of Medicine

Tucson, Arizona, United States, 85724

United States, California

UCSD School of Medicine

LaJolla, California, United States, 92093

United States, Colorado

National Jewish Medical and Research Center

Denver, Colorado, United States, 80206

United States, Missouri

Washington University School of Medicine Patient Oriented Research Unit

St. Louis, Missouri, United States, 63110

United States, Pennsylvania

Dept. of Health Evaluation Sciences, Penn State College of Medicine

Hershey, Pennsylvania, United States, 17033

United States, Wisconsin

University of Wisconsin - Madison

Madison, Wisconsin, United States, 53792

Sponsors and Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

• Principal Investigator: Vernon M. Chinchilli, PhD; Pennsylvania State University, College of Medicine

More Information

Publications of Results:

Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD, Lemanske RF Jr, Sorkness CA, Bloomberg GR, Morgan WJ, Paul IM, Guilbert T, Krawiec M, Covar R, Larsen G, Mellon M, Moss MH, Chinchilli VM, Taussig LM, Strunk RC; CARE Network. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol. 2008 Dec;122(6):1127-1135.e8. doi: 10.1016/j.jaci.2008.09.029. Epub 2008 Oct 30.

• Responsible Party: Vernon M. Chinchilli, PhD, Pennsylvania State University, College of Medicine
• ClinicalTrials.gov Identifier: NCT00319488
• Other Study ID Numbers: 386; 5U10HL064313-07 ( U.S. NIH Grant/Contract ); 5U10HL064287 ( U.S. NIH Grant/Contract ); 5U10HL064307 ( U.S. NIH Grant/Contract ); 5U10HL064305 ( U.S. NIH Grant/Contract ); 5U10HL064288 ( U.S. NIH Grant/Contract ); 5U10HL064295 ( U.S. NIH Grant/Contract )
• First Posted: April 27, 2006
• Last Update Posted: July 29, 2016
• Last Verified: April 2012

Keywords provided by National Heart, Lung, and Blood Institute (NHLBI):

Wheezing; Respiratory Tract Illness

Additional relevant MeSH terms:

Asthma; Lung Diseases; Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Budesonide; Albuterol; Montelukast; Leukotriene Antagonists; Anti-Inflammatory Agents; Bronchodilator Agents; Autonomic Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anti-Asthmatic Agents; Respiratory System Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hormone Antagonists; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 Enzyme Inducers; Molecular Mechanisms of Pharmacological Action; Tocolytic Agents; Reproductive Control Agents; Adrenergic beta-2 Receptor Agonists